Trisomy 21, 18, 13

The present blood sample will be screened for the presence of fetal trisomy 21, 18 and 13 (Illumina, verifi technology) after extraction of cell-free DNA and generation of a genomic library using Next-Generation sequencing (NGS). The condition for reimbursement by obligatory health insurance (OHI) is that a first trimester test (measurement of the nuchal translucency in the ultrasound, determination of free beta-hCG and PAPP-A in the blood of the pregnant woman) is carried out beforehand and that it has been shown that the risk of trisomies 21, 18 or 13 is greater than 1:1000. No cost reimbursement for twins. Upon request of the pregnant woman the test can also be carried out from WOP 9+1 as a self-payment service. Communication of the gender only takes place after WOP 12.